To maximize Series A runway, biotech investors must look for this key trait
To get to Series B, biotechs must kill dead-end projects fast: prior success + failure predict which shave years of waste
To maintain SaaS growth, sometimes less R&D is actually more
Moderating R&D partnerships adds another 10-20% to share of revenue from new products, crucial for SaaS firms
Basing remote salary on geography? There may be a less contentious solution
Break room magic - pharma office layout has huge impact on R&D returns
When digital patent seeking can be the new lifeblood of non-tech industries
Easy way to make high-burnout employees into low-turnover ones
Big Value in Big Data? Here's how to signal the market about it
![The spin-off brain drain, when it is [and isn't] worth it](https://images.squarespace-cdn.com/content/v1/64b968f77321602fb2f87390/1704515547531-IHZAJP5HHVCQYXUB1E45/iStock-staff+redeployment.jpeg)
The spin-off brain drain, when it is [and isn't] worth it
